<DOC>
	<DOC>NCT01784107</DOC>
	<brief_summary>Phase 1 : To evaluate MTD(Maximal tolerated dose)and DLT(Dose limiting Toxicity) of Belotecan and Ifosfamide. Phase 2 : To analyse efficacy and toxicity of Belotecan and Ifosfamide.</brief_summary>
	<brief_title>A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Belotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>histologically or cytologically confirmed extensive disease of Small cell lung cancer no prior chemotherapy or radiotherapy for lung measurable lesion for RECIST over 18 years ECOG 0~2 expected life span more than 3 months acute or active infection uncontrolled cerebral nerve symptoms or metastasis significant myocardial infarction or cardiac disease within 12 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>SCLC</keyword>
	<keyword>belotecan</keyword>
	<keyword>Ifosfamide</keyword>
</DOC>